Abstract
Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a proxy NAFLD definition of chronic alanine aminotransferase elevation (cALT) without other liver diseases, we performed a trans-ancestry genome-wide association study in the Million Veteran Program including 90,408 cALT cases and 128,187 controls. In the Discovery stage, seventy-seven loci exceeded genome-wide significance – including 25 without prior NAFLD or ALT associations – with one additional locus identified in European-only and two in African-American-only analyses (P<5×10-8). External replication in cohorts with NAFLD defined by histology (7,397 cases, 56,785 controls) or liver fat extracted from radiologic imaging (n=44,289) validated 17 SNPs (P<6.5×10-4) of which 9 were novel (TRIB1, PPARG, MTTP, SERPINA1, FTO, IL1RN, COBLL1, APOH, and IFI30). Pleiotropy analysis showed that 61 of 77 trans-ancestry and all 17 validated SNPs were jointly associated with metabolic and/or inflammatory traits, revealing a complex model of genetic architecture. Our approach integrating cALT, histology and imaging reveals new insights into genetic liability to NAFLD.
Competing Interest Statement
H.R.K. is a member of a Dicerna scientific advisory board, a member of the American Society of Clinical Psychopharmacologys Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka, and is named as an inventor on PCT patent application 15/878,640 entitled Genotype-guided dosing of opioid agonists, filed January 24, 2018. D.G. is employed part-time by Novo Nordisk.
Funding Statement
This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration and was supported by award no. MVP000. This publication does not represent the views of the Department of Veterans Affairs, the US Food and Drug Administration, or the US Government. This research was also supported by funding from: the Department of Veterans Affairs awards I01- BX003362 (P.S.T. and K.M.C) and I01BX003341 (H.R.K. Co-Principal Investigator) and the VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 130457 (S.L.D). B.F.V. acknowledges support for this work from the NIH/NIDDK (DK101478 and DK126194) and a Linda Pechenik Montague Investigator award. K.M.C, S.M.D, J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is supported by the Veterans Administration [IK2 CX001780]. Funding support is also acknowledged for MS (K23 DK115897), R.M.C (R01 AA026302), D.K. (National Heart, Lung, and Blood Institute of the National Institutes of Health [T32 HL007734]), L.S.P. (VA awards I01 CX001025, and I01 CX001737, NIH awards R21 DK099716, U01 DK091958, U01 DK098246, P30 DK111024, and R03 AI133172, and a Cystic Fibrosis Foundation award PHILLI12A0). The Rader lab was supported by NIH grants HL134853 (NJH and DJR) and DK114291-01A1 (K.T.C, N.J.H, and D.J.R). We thank all study participants for their contribution. Support for imaging studies was provided by ITMAT (NIH NCATS UL1TR001878), the Penn Center for Precision Medicine Accelerator Fund and R01 HL137501. Data for external replication and hepatic fat concordance were provided by investigators using United Kingdom BioBank, Multi-Ethnic Study of Atherosclerosis (MESA), Old Order Amish Study (Amish), Framingham Heart Study (FHS) and Penn Medicine Biobank (PMBB). MESA/MESA SHARe Acknowledgements: MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. This research was supported by R01 HL071739 and MESA was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. Also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies have received ethical and study protocol approval from their respective institutional review boards (IRBs) in accordance with the principles outlined in the Declaration of Helsinki. The Million Veteran Program (MVP) received approval its study protocol by the Veterans Affairs Central IRB, and by the IRBs at each field center where all participants gave written informed consent. All local R&D IRB committees are: Corporal Michael J. Crescenz VA Medical Center; VA Palo Alto Health Care System; VA Salt Lake City Health Care System; Edith Nourse Rogers Memorial Veterans Hospital; Phoenix VA Health Care System; Atlanta VA Medical Center; VA Boston Healthcare System; and the North Florida / South Georgia Veterans Health System. The study protocol for the Penn Medicine Biobank (PMBB) was approved by the IRB of the University of Pennsylvania. Informed consent was obtained from each study participant. The study protocol for the Older Order Amish study was approved by the IRB at the University of Maryland Baltimore. Informed consent was obtained from each study participant. The Framingham Heart Study (FHS) study protocol was approved by the IRB of the Boston University Medical Center. All study participants provided written informed consent. All participants of the Multi-Ethnic Study of Atherosclerosis (MESA) provided written informed consent, and the study was approved by the IRBs at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference number 11/NW/0382). Use of UK Biobank data (application 7089) was approved by the local Mass General Brigham IRB. NASH CRN Acknowledgements: The NASH CRN database and clinical trials were reviewed and approved by the individual institutional review boards at each participating site. All participants signed an informed consent prior to their enrollment into these consents and their de-identified genetic data to be used for future liver disease research by the NASH CRN investigators and by their collaborators. These studies have been monitored by an NIDDK-sponsored data safety and monitoring board. The NASH Boys study was supported by NIDDK (U01DK061734, U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061737, U01DK061738, U01DK061730, U01DK061713) and NICHD. It was also supported by NIH CTSA awards (UL1TR000040, UL1RR024989, UL1RR025761, M01RR00188, UL1RR024131, UL1RR025014, UL1RR031990, UL1RR025741, UL1RR029887, UL1RR24156, UL1RR025055, UL1RR031980), and DRC HDK063491. LQTS was supported by the National Institutes of Health (grant 5R42HL112435-04 to QT Medical, Inc.). The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. For LQTS: QT Medical, Inc., was involved in the study design and collection of data. However, QT Medical, Inc., had no involvement in the analysis and interpretation of the data, the drafting of the article, or the decision to submit the article for publication. The FLINT trial was conducted by the NASH CRN and supported in part by a Collaborative Research and Development Agreement (CRADA) between NIDDK and Intercept Pharmaceuticals. The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grants U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713). Additional support is received from the National Center for Advancing Translational Sciences (NCATS) (grants UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058). The PIVENS study was supported by grants from the National Institutes of Health to the NASH Clinical Research Network (U01DK61718, U01DK61728, U01DK61731, U01DK61732, U01DK61734, U01DK61737, U01DK61738, U01DK61730, U01DK61713) and, in part, by the intramural program on the NIH, National Cancer Institute. Other grant support includes the following National Institutes of Health General Clinical Research Centers or Clinical and Translational Science Awards: UL1RR024989, UL1RR024128, M01RR000750, UL1RR024131, M01RR000827, UL1RR025014, M01RR000065. Additional funding to conduct PIVENS trial was provided by Takeda Pharmaceuticals North America, Inc. through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health. The vitamin E softgels and matching placebo were provided by Pharmavite, LLC through a Clinical Trial Agreement with the National Institutes of Health. The NASH women study was supported by U01DK061737 and K24DK069290 (N.C.), NCRR grant M01-RR00425 to the Cedars-Sinai General Research Center Genotyping core, P30DK063491 to J.R., and R01DK079888 to M.O.G. This work is supported in part by the American Gastroenterological Association (AGA) Foundation, Sucampo, ASP Designated Research Award in Geriatric Gastroenterology, and by a T. Franklin Williams Scholarship Award; Funding provided by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of Specialty Professors, and the American Gastroenterological Association to R.L. This research was funded in part with the support of the UCSD Digestive Diseases Research Development Center, US PHS grant DK080506. The CAP study was supported by the National Institutes of Health: grant U19 HL069757 from the National Heart, Lung, and Blood Institute; and grant UL1TR000124 from the National Center for Advancing Translational Sciences. EPoS Acknowledgements: The EPoS genetics study and the European NAFLD Registry haves been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the European Union Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the FLIP (Fatty Liver: Inhibition of Progression) consortium funded by the (European Union FP7 under grant agreement 241762), the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 Joint Undertaking that receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA under grant agreement 777377, and the Newcastle NIHR Biomedical Research Centre. Gilead Acknowledgements: The Stellar and Atlas were funded by Gilead Sciences, Inc. Regeneron Acknowledgements: The Geisinger Health System bariatric-surgery biobank was funded by Regeneron Pharmaceuticals and partly supported by a grant (P30DK072488) from the Mid-Atlantic Nutrition Obesity Research Center by the National Institutes of Health (NIH). Penn Medicine Biobank Acknowledgements: The Penn Medicine BioBank is funded by the Perelman School of Medicine at the University of Pennsylvania and by a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878." BioVU Acknowledgements: The Vanderbilt University Medical Centers BioVU projects are supported by institutional funding, private agencies, and federal grants, which include the NIH funded Shared Instrumentation Grant S10OD017985 and S10RR025141; CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975; and investigator-led projects U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; U01 HG004603; U01 HG006378.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
added liver biopsy cohort for replication; removed replication with PMBB data; merged discovery and internal replication stages into discovery analysis only; supplemental tables updated; supplemental figures updated; figure 1 revised; figure 2 revised; figure 3 revised; figure 4 updated; rewritten discussion; added authors; revised abstract; revised introduction.
Data Availability
The full summary level association data from the trans-ancestry, European, African American, Hispanic, and Asian meta-analysis from this report will be available through dbGAP project number phs001672.v4.p1 (study-specific accession codes will be available before publication).
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/analysis.cgi?study_id=phs001672.v4.p1
